Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced ...
Conclusions: AXL improved white matter injury after ischemic stroke by promoting microglial phagocytosis of myelin debris and mediating intracellular cholesterol metabolism.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback